Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic
出版年份 2020 全文链接
标题
Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume -, Issue -, Pages annrheumdis-2020-219217
出版商
BMJ
发表日期
2020-10-15
DOI
10.1136/annrheumdis-2020-219217
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
- (2020) Achille Aouba et al. ANNALS OF THE RHEUMATIC DISEASES
- Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
- (2020) Gian Luca Erre et al. ANNALS OF THE RHEUMATIC DISEASES
- Are my patients with rheumatic diseases at higher risk of COVID-19?
- (2020) Gabriel Figueroa-Parra et al. ANNALS OF THE RHEUMATIC DISEASES
- Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
- (2020) Wenhui Xie et al. ANNALS OF THE RHEUMATIC DISEASES
- The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capeechi et al
- (2020) Sara Monti et al. ANNALS OF THE RHEUMATIC DISEASES
- Hydroxychloroquine shortages during the COVID-19 pandemic
- (2020) Arielle Mendel et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatic diseases in intensive care unit patients with COVID-19
- (2020) Sergey Moiseev et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘Hydroxychloroquine shortages during the COVID-19 pandemic’ by Mendel et al
- (2020) Iain McInnes ANNALS OF THE RHEUMATIC DISEASES
- SLE, hydroxychloroquine and no SLE patients with covid-19: a comment
- (2020) Beuy Joob et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China
- (2020) Cong Ye et al. ANNALS OF THE RHEUMATIC DISEASES
- Patients with lupus are not protected from COVID-19
- (2020) Amr H Sawalha ANNALS OF THE RHEUMATIC DISEASES
- SLE patients are not immune to covid-19: importance of sending the right message across
- (2020) Mohit Goyal ANNALS OF THE RHEUMATIC DISEASES
- To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic
- (2020) Francesca Romana Spinelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
- (2020) Sara Monti et al. ANNALS OF THE RHEUMATIC DISEASES
- Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
- (2020) Carlo Salvarani et al. ANNALS OF THE RHEUMATIC DISEASES
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic
- (2020) George E Fragoulis et al. ANNALS OF THE RHEUMATIC DISEASES
- No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic’ by Santos-Moreno et al
- (2020) Emanuele Bozzalla Cassione et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
- (2020) Pier Leopoldo Capecchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Rational use of tocilizumab in COVID-19
- (2020) Siddharth Jain et al. ANNALS OF THE RHEUMATIC DISEASES
- Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments
- (2020) Zoé Gendebien et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases’ by Lopez-Medina et al
- (2020) Emanuele Bozzalla Cassione et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases
- (2020) Clementina López-Medina et al. ANNALS OF THE RHEUMATIC DISEASES
- Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
- (2020) Marlene Plüß et al. ANNALS OF THE RHEUMATIC DISEASES
- Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
- (2020) Jose L Pablos et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
- (2020) Carlos Sanchez-Piedra et al. ANNALS OF THE RHEUMATIC DISEASES
- Telemedicine will not keep us apart in COVID-19 pandemic
- (2020) Simone Perniola et al. ANNALS OF THE RHEUMATIC DISEASES
- Biologics, spondylitis and COVID-19
- (2020) James Todd Rosenbaum et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 in patients with rheumatological diseases treated with anti-TNF
- (2020) Carlos Antunes Brito et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy
- (2020) Sophie Benoy et al. ANNALS OF THE RHEUMATIC DISEASES
- Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al
- (2020) Vasco C Romão et al. ANNALS OF THE RHEUMATIC DISEASES
- Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients
- (2020) Ennio Giulio Favalli et al. ANNALS OF THE RHEUMATIC DISEASES
- Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
- (2020) Carmen Magdalena Gamboa-Alonso et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
- (2020) Arielle Mendel et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic
- (2020) Richard Oluyinka Akintayo et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre
- (2020) Natasha Cleaton et al. ANNALS OF THE RHEUMATIC DISEASES
- Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
- (2020) Sofia Ramiro et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 infection in a patient with FMF: does colchicine have a protective effect?
- (2020) Senol Kobak ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al
- (2020) Sofia Ramiro et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al
- (2020) Silvia Piantoni et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
- (2020) Adrian Ciurea et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation–an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang
- (2020) Emanuel Della-Torre et al. ANNALS OF THE RHEUMATIC DISEASES
- Preliminary predictive criteria for COVID-19 cytokine storm
- (2020) Roberto Caricchio et al. ANNALS OF THE RHEUMATIC DISEASES
- High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab
- (2020) Edoardo Conticini et al. ANNALS OF THE RHEUMATIC DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started